In one paragraphArticle in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Meztlli O GaytánDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm SE-171 65, Sweden.ORCID 0000-0003-3636-1919 Rebecca S DookieDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm SE-171 65, Sweden.ORCID 0000-0001-7850-2543 Sayoni ChakrabortyDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm SE-171 65, Sweden.
Anandi Narayana MoorthyDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm SE-171 65, Sweden.
Stefan KreidaDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm SE-171 65, Sweden.
Anna Norrby-TeglundCenter for Infectious Medicine, Department of Medicine, Alfred Nobels Allé Futura, Karolinska Institutet, Karolinska University Hospital, Huddinge SE-141 52, Sweden.ORCID 0000-0001-9372-1795 John BossDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm SE-171 65, Sweden.
Max HeurgrenDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm SE-171 65, Sweden.
Staffan NormarkDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm SE-171 65, Sweden.ORCID 0000-0001-7917-3921 Birgitta Henriques-NormarkDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm SE-171 65, Sweden.ORCID 0000-0002-5429-4759 Funding
Knut och Alice Wallenberg foundation (KAW) KAW2022.0227Region Stockholm FoUI-985773The Swedish Foundation for Strategic research (SSF) RMX18-0041007The Swedish Research Council 2018-05798;2020-01342;2021-02059;2023-01975Torsten Söderberg Foundation Akademiprofessur
6 · The paper itselfAbstract
An effective vaccine against
Indexed as
Antigens, BacterialExtracellular VesiclesStreptococcal InfectionsStreptococcus pyogenesAnimalsAntibodies, BacterialBacterial ProteinsFemaleHumansImmunoglobulin AImmunoglobulin GInterleukin-17MiceStreptococcal VaccinesTh17 CellsAntibodies, BacterialAntigens, BacterialBacterial ProteinsImmunoglobulin AImmunoglobulin GInterleukin-17Streptococcal Vaccinesextracellular vesiclesStreptococcus pyogenesvaccine
Identifiers
PMID42118829
PMCPMC13187779
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390